Key result
CD40L expressed by platelets in vivo upon contact with a damaged vessel wall activates endothelium, and this mechanism is not inhibited by aspirin treatment.
Why the study?
Does aspirin 500 mg inhibit platelet CD40L expression and endothelial activation at a site of vascular injury in healthy volunteers?
Population
Healthy volunteers undergoing skin-bleeding-time test to model localized vascular injury
Comparison
Aspirin 500 mg single dose vs Baseline (before aspirin intake)
Design
Other
Follow-up
1 hour
Authors
Loading...
High-dose aspirin may not block platelet CD40L endothelial activation at injury sites; leaves open CD40L-targeted therapies in atherothrombosis.
Does aspirin 500 mg inhibit platelet CD40L expression and endothelial activation at a site of vascular injury in healthy volunteers?
Aspirin does not inhibit platelet CD40L expression at sites of vascular injury, suggesting alternative pathways may be needed to prevent platelet-mediated endothelial activation in atherothrombosis.
Giannini et al. (2011) studied Healthy volunteers. Aspirin vs. Baseline (before intake) was evaluated on Platelet CD40L expression and endothelial activation. CD40L expressed by platelets in vivo upon contact with a damaged vessel wall activates endothelium, and this mechanism is not inhibited by aspirin treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: